Sumitomo Pharma America
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sumitomo Pharma America sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Sumitomo Pharma America: 168 sponsored US clinical trials, 6 recruiting.
Sumitomo Pharma America sponsors 168 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 142 completed. 83 of these trials are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 4 trials.
Top-decile sponsor footprint
Sumitomo Pharma America ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
142 of 159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 4 of 4
Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma
NCT00685022
Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects
NCT00667797
Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects
NCT00685347
Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma
NCT00684866
Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma
NCT00064389
Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma
NCT00073840
Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma
NCT00073814
A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma
NCT00684827
Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol
NCT00685425
Safety and Tolerability Study of Drug to Treat Schizophrenia
NCT00044005
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
NCT00044044
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
NCT00064415
Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma
NCT00073827
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
NCT00064402
A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00685841
Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)
NCT00665600
Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)
NCT00685126
Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma
NCT00667407
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 27 |
| Phase 3 | 75 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Sumitomo Pharma America pipeline
6 recruiting of 168 indexed (4% open); 142 completed (85%).
Phase mix: 83 late (III/IV) vs 80 early (I/II) (balanced across stages).
Top condition: Schizophrenia (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sumitomo Pharma America: open-pipeline peers nationwide
Peers matched on 168 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Sumitomo Pharma America sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Bayer · 4% recruiting · 591 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
Related
What to do with this Sumitomo Pharma America page
168 registered trials is a research-attention snapshot, not an endorsement of Sumitomo Pharma America or any single study.
- 6 of Sumitomo Pharma America's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Sumitomo Pharma America studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sumitomo Pharma America pipeline card: 168 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.